Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 20, 2026

Study Completion Date

July 31, 2027

Conditions

HPV 16+ Recurrent or Metastatic CancerHNSCCCervical Cancer

Interventions

BIOLOGICAL

therapeutic tumor vaccine

TI-0093 injection will be administered intramuscularly on Day1, Day8, Day15, Day29 and Day43.

Trial Locations (1)

Shanghai East Hospital, Shanghai